The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC

Lung Cancer

Volumn 60, Issue 3, 2008, Pages 393-400

  Kim, Se Hyun ^a,b,c   Cho, Byoung Chul ^a,b,c   Choi, Hye Jin ^a,b,c   Chung, Kyung Young ^b,c   Kim, Dae Joon ^b,c   Park, Moo Suk ^b,c   Kim, Se Kyu ^b,c   Chang, Joon ^b,c   Shin, Sang Joon ^a,b,c   Sohn, Joo Hyuk ^a,b   Kim, Joo Hang ^a,b,c  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Downstaging; Lymph node; Neoadjuvant chemotherapy; NSCLC; Prognostic; Stage III; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; PACLITAXEL; PLATINUM; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; ASTHENIA; CANCER CLASSIFICATION; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; MEDIASTINOSCOPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PLEURA EFFUSION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RADIATION DOSE; THORACOTOMY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; URTICARIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; PACLITAXEL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS; VINBLASTINE;

EID: 44249100649     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.11.004     Document Type: Article

References (28)

1. Farray D., Mirkovic N., and Albain K.S. Multimodality therapy for stage III non-small-cell lung cancer. J Clin Oncol 23 (2005) 3257-3269
2. Rosell R., Gomez-Codina J., Camps C., Maestre J., Padille J., Canto A., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330 (1994) 153-158
3. Roth J.A., Fossella F., Komaki R., Bernadette Ryan M., Putnam Jr. J.B., Lee J.S., et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86 (1994) 673-680
4. Depierre A., Milleron B., Moro-Sibilot D., Chevret S., Quoix E., Lebeau B., et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 20 (2002) 247-253
5. Berghmans T., Paesmans M., Meert A., Mascaux C., Lothaire P., Lafitte J.J., et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 49 (2005) 13-23
6. Grunenwald D., Andre F., Le Ṕechoux C., Girard P., Lamer C., Laplanche A., et al. Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. J Thorac Cardiovasc Surg 122 (2001) 796-802
7. Trodella L., Granone P., Valente S., Margaritora S., Macis G., Cesario A., et al. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging. Ann Oncol 15 (2004) 389-398
8. Sugarbaker D.J., Herndon J., Kohman L.J., Krasna J.M., and Green M.R. Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. J Thorac Cardiovasc Surg 109 (1995) 473-485
9. Betticher D.C., Hsu Schmitz S.F., Totsch M., Hansen E., Joss C., von Briel C., et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 21 (2003) 1752-1759
10. Barlesi F., Doddoli C., Torre J.P., Giudicelli R., Fuentes P., Thomas P., et al. Comparative prognostic features of stage IIIAN2 and IIIB non-small-cell lung cancer patients treated with surgery after induction therapy. Eur J Cardiothorac Surg 28 (2005) 629-634
11. Takeda S., Maeda H., Okada T., Yamaguchi T., Nakagawa M., Yokota S., et al. Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer. Eur J Cardiothorac Surg 30 (2006) 184-189
12. Betticher D.C., Hsu Schmitz S.F., Totsch M., Hansen E., Joss C., von Briel C., et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 94 (2006) 1099-1106
13. Jaklitsch M.T., Herndon II J.E., Decamp Jr. M.M., Richards W.G., Kumar P., Krasna M.J., et al. Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935. J Surg Oncol 94 7 (2006) 599-606
14. Gu Y., Swisher S.G., Ajani J.A., Correa A.M., Hofstetter W.L., Liao Z., et al. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer 106 (2006) 1017-1025
15. Kuerer H.M., Newman L.A., Buzdar A.U., Hunt K.K., Dhingra K., Buchholz T.A., et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 176 (1998) 502-509
16. Liersch T., Langer C., Ghadimi B.M., Kulle B., Aust D.E., Baretton G.B., et al. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemotherapy. J Clin Oncol 24 (2006) 4062-4068
17. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
18. In: Greene F.L., Page D.L., Fleming I.D., Fritz A., Balch C.M., Haller D.G., et al. (Eds). AJCC cancer staging manual. 6th ed. (2002), Springer-Verlag, New York
19. Gupta N.C., Tamin W.J., Graeber G.G., Bishop H.A., and Hobbs G.R. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest 120 (2001) 521-527
20. De Marinis F., Nelli F., Migliorino M.R., Martelli O., Cortesi E., Treggiari S., et al. Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven Stage IIIA (N2) nonsmall cell lung carcinoma: a Phase II multicenter study. Cancer 98 (2003) 1707-1715
21. Albain K.S., Swann R.S., Rusch V.R., Turrisi A.T., Shepherd F.A., Smith C.J., et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs. CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer: outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol 23 16S (2005) 624S [abstract 7014]
22. van Meerbeeck J.P., Kramer G.W., Van Schil P.E., Legrand C., Smit E.F., Schramel F., et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 99 (2007) 442-450
23. Junker K., Langner K., Klinke F., Bosse U., and Thomas M. Grading of tumor regression in non-small cell lung cancer: morphology and prognosis. Chest 120 (2001) 1584-1591
24. Stinchcombe T.E., Morris D.E., Moore D.T., Bechtel J.H., Halle J.S., Mears A., et al. Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy. Lung Cancer 52 (2006) 67-74
25. Pauwels M., Van Schil P., De Backer W., Van den Brande F., and Eyskens E. Repeat mediastinoscopy in staging of lung cancer. Eur J Cardiothorac Surg 14 (1998) 271-273
26. Mateu-Navarro M., Rami-Porta R., Bastus-Piulats R., Cirera-Noqueras L., and Gonzalez-Pont G. Remediastinoscopy after induction chemotherapy in non-small cell lung cancer. Ann Thorac Surg 70 (2000) 391-395
27. Pitz C.C., Maas K.W., Van Swieten H.A., de la Riviere A.B., Hofman P., and Schramel F.M. Surgery as part of combined modality treatment in stage IIIB nonsmall cell lung cancer. Ann Thorac Surg 74 (2002) 164-169
28. De Leyn P., Stroobants S., De Wever W., Lerut T., Coosemans W., Decker G., et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol 24 (2006) 3333-3339